PACE-NODES

Name No. For Patients with Purpose
PACE-NODES 23-01

High risk localised prostate cancer, deemed suitable for SBRT radiotherapy and planned for 12 – 36 months androgen deprivation therapy

This study will compare the safety and efficacy of curative radiotherapy to the prostate and lymph glands given in 5 visits to that of prostate alone radiotherapy given in 5 visits, in men with high risk localised prostate cancer.


LIAM Mc Trial

Name No. For Patients with Purpose
LIAM Mc Trial 23-18

Advanced / metastatic genitourinary cancer (including prostate, kidney, urothelial tract, testicular and/or penile cancers)

To evaluate the feasibility of introducing a men’s cancer survivorship program into routine follow up care in patients with advanced genitourinary malignancies.


PEACE 6 – Vulnerable

Name No. For Patients with Purpose
PEACE 6 – Vulnerable 20-32

Castration-naïve de novo metastatic prostate cancer patients with vulnerable functional ability who have not elected for docetaxel or other androgen receptor pathway inhibitors

The purpose of the trial is to evaluate the efficacy and safety of ADT +/- darolutamide in castration-naïve de novo metastatic prostate cancer patients with vulnerable functional ability.


SLECT

Name No. For Patients with Purpose
SLECT 23-09

Testicular cancer treated with either surgery, chemotherapy or radiotherapy and completed 5 years of surveillance.

To determine incidence of late complications in testicular cancer survivors of Ireland.


MK3475-905 (KEYNOTE-905)

Name No. For Patients with Purpose
MK3475-905 (KEYNOTE-905) 20-16

Cisplatin-Ineligible or Decline Cisplatin With Muscle-Invasive Bladder Cancer

To Evaluate Cystectomy With Perioperative Pembrolizumab and Cystectomy With Perioperative Enfortumab Vedotin and Pembrolizumab Versus Cystectomy Alone in Participants Who Are Cisplatin-Ineligible or Decline Cisplatin With Muscle-Invasive Bladder Cancer


SABRE

Name No. For Patients with Purpose
SABRE 22-11

Prostate Cancer being Treated with Stereotactic Body Radiotherapy

To demonstrate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in subjects undergoing Stereotactic Body Radiotherapy (SBRT) to treat prostate cancer.


MK3475-365

Name No. For Patients with Purpose
MK3475-365 21-20

Metastatic Castrate Resistant Prostate Cancer (mCRPC).

The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in patients with metastatic castrate resistant prostate cancer (mCRPC).


IMvigor011 B042843

Name No. For Patients with Purpose
IMvigor011 B042843 21-38

High-Risk Muscle-Invasive Bladder Cancer Who are ctDNA Positive Following Cystectomy (IMvigor011)

The purpose of this trial is to evaluate the efficacy and safety of adjuvant treatment with Atezolizumab compared with placebo in participants with MIBC who are ctDNA positive and are at high risk for recurrence following cystectomy.


MK6482-022

Name No. For Patients with Purpose
MK6482-022 21-37

Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy

The purpose of this study is to assess the efficacy and safety of oral Belzutifan (MK-6482) plus intravenous (IV) Pembrolizumab (MK-3475) compared to placebo plus Pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post nephrectomy.


IRONMAN: International Registry for Men with Advanced Prostate Cancer

Name No. For Patients with Purpose
IRONMAN: International Registry for Men with Advanced Prostate Cancer CTRIAL-IE 17-30

Metastatic hormone-sensitive prostate cancer (mHSPC) or castration-resistant prostate cancer (CRPC)

The purpose of this study is to create an international, population-based,
prospective registry of minimum 5,000 men with advanced prostate cancer.